# Aluna

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aluna

- Industry: Medical Devices & Equipment
- Headquarters: San Francisco, US
- Website: www.alunacare.com
- Total disclosed funding: $21M
- Latest round: Series B (Dec 8, 2022)
- Investors on record: 7

## About

Aluna, based in the US, is a healthcare technology company that focuses on chronic lung conditions, delivering innovative solutions to empower patients in managing their respiratory health effectively.Aluna specializes in digital health for individuals with chronic lung conditions, providing tools for monitoring and improving lung health. Founded in 2013 in San Francisco, US, the company has completed 7 deals, with the most recent funding round being a Series B in December 2022, raising USD 15.28 mn from investors including Matrix Partners, Blue Bear Ventures, and RHO Capital Partners. The founders, Charvi Shetty, Inderjit Jutla, and María Ripoll, along with CEO Charvi Shetty, have previously worked in diverse fields, leveraging their expertise in healthcare innovation.Aluna's primary product is a digital spirometer designed for individuals with chronic lung conditions such as asthma and cystic fibrosis. This innovative device allows users to measure their lung health with hospital-grade accuracy from the comfort of their homes. The spirometer connects seamlessly to a mobile application via Bluetooth, enabling users to track their FEV1%—a key measure of lung function—over time. In addition to lung function tracking, the app provides features that allow users to monitor symptoms, medication usage, exercise routines, and environmental factors that may impact their respiratory health. Aluna aims to empower patients by providing valuable insights that can prevent asthma attacks and reduce unnecessary emergency room visits. The product is marketed primarily to patients in the United States, with an emphasis on enhancing the quality of life for those living with respiratory conditions.Aluna's revenue model is structured around direct-to-consumer sales of its digital spirometer and associated mobile application. Customers can purchase the spirometer either as a standalone device or as part of a subscription service that offers additional features such as personalized health monitoring and data sharing capabilities with healthcare providers. The company engages in partnerships with healthcare professionals and institutions to enhance distribution and reach a broader client base. Revenue is generated through the sale of the spirometer and recurring subscriptions for the app, which may include premium features tailored to user needs. Aluna's flagship product, the digital spirometer, is central to its revenue strategy, targeting both individuals and families managing chronic lung conditions.In December 2022, Aluna raised USD 15.28 mn in Series B funding, led by Matrix Partners with participation from Blue Bear Ventures and new investor RHO Capital Partners. The funding will be utilized for product innovation and to expand their offerings from asthma management to include Chronic Obstructive Pulmonary Disease (COPD) and cystic fibrosis. Aluna plans to develop new products to enhance their current spirometer capabilities and target further geographic expansion into additional markets over the next few years.

## Funding rounds

- Series B, Dec 8, 2022, $15M — Matrix Partners, RHO, Blue Bear Ventures
- Series A, Oct 28, 2020 — SOSV, IndieBio
- Series A, Dec 1, 2018, $2.3M — Good Growth Capital
- Seed, Jun 1, 2018, $3.5M — Blue Bear Ventures
- Seed, Sep 9, 2016 — Bolt
- Seed, Jan 21, 2016 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed, Series A
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed, Series A
- Bolt (https://capitalatlas.ai/funds/bolt) — Seed
- Blue Bear Ventures (https://capitalatlas.ai/funds/blue-bear-ventures) — Seed, Series B
- Good Growth Capital (https://capitalatlas.ai/funds/good-growth-capital) — Series A
- Matrix Partners (https://capitalatlas.ai/funds/matrix-partners) — Series B
- RHO (https://capitalatlas.ai/funds/rho) — Series B